secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2026-08-06T20:08:16+00:00
Accession:  0001159036-26-000103
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme reports record Q2 2026: revenue $481M (+48% YoY), raises full-year guidance
--------------------------------------------------------------------------------

- Q2 total revenue $481M (+48% YoY); royalty revenue $308M (+50% YoY); GAAP diluted EPS $1.90, non-GAAP $2.28.
- Adjusted EBITDA $329M (+46% YoY); operating income $288M.
- Raised FY2026 guidance: total revenue $1.835-1.910B, royalty $1.220-1.245B, non-GAAP EPS $8.65-9.00.
- Signed five new ENHANZE/Hypercon collaborations YTD (Vertex, Oruka, GSK, Incyte, undisclosed), exceeding full-year goal of three.
- Repurchased $333M of shares in Q2 at avg $69.30; new $1B buyback program announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903626000103/0001159036-26-000103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903626000103/halo-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001159036-26-000103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer